AstraZeneca stock (AZN) will start trading on the New York Stock Exchange (NYSE) today, replacing its Nasdaq-listed ADRs. With this move, the company is aiming to attract more investors by leaning further into the U.S. market, which already accounts for nearly half of its revenue. AstraZeneca also said the change will give equal weight to its UK, Swedish, and U.S. listings.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
What It Means for US Investors
While the move does not change AstraZeneca’s business fundamentals, it can improve how the stock trades in the U.S.
For U.S. investors, an ADR is essentially a bank-issued receipt that represents foreign shares held overseas, which can come with small fees and sometimes lower liquidity. A direct U.S. listing, by contrast, allows investors to buy the company’s actual shares in the U.S. market, often with better liquidity, no ADR fees, clearer ownership rights, and greater visibility among large U.S. investors.
The company told shareholders it hopes the new listing will help U.S. investors participate more directly in its “strong growth.” Notably, the company has pledged to invest $50 billion in the U.S. by 2030 amid tariff pressures.
AZN Stays Upbeat on New NYSE Listing
Michel Demare, chairman of AstraZeneca, said the move marks the start of a new chapter for the company, giving it broader access to the world’s largest capital market. Demare also stated that the unified listing in New York, London, and Stockholm shows strong support from shareholders for the company’s strategy.
Is AZN a Good Stock to Buy Now?
According to TipRanks, AZN stock has received a Strong Buy consensus rating, with five Buys assigned in the last three months. AstraZeneca’s average stock price target is $106.75, suggesting an upside of 15% from the current level.
